ITEM METADATA RECORD
Title: Bioanalysis for Biosimilars Development
Editors: Declerck, Paul
Issue Date: 2015
Publisher: Future Science Group
Abstract: According to PubMed, the term ‘biosimilar’ has existed for 10 years in scientific literature, with the first biosimilar having been introduced onto the European market in 2006. Early biosimilars concerned relatively small proteins such as human growth hormone, epoetin and filgrastim. In 2013, the first biosimilar monoclonal antibody (infliximab) was approved. It is beyond any doubt that the emergence of biosimilars has an important impact on biopharmaceutical companies involved in the production of biotechnological medicines. This is also illustrated by the fact that biosimilars from blockbuster drugs are currently also being developed by competing ‘originator’ companies.

Bringing copies of off-patent biotechnological drugs to the market has required the development of particular guidelines by regulatory authorities. Chapters 1–3 in this e-book cover the various aspects of these issues, and the consequences for biosimilar development and the analytical requirements. The concept of biosimilar development is based on a very detailed, thorough analytical comparison between the biosimilar and its reference product. General aspects that need to be taken into account and particular concerns (e.g., analysis of glycosylation patterns) regarding physicochemical characterization are discussed in Chapter 4. Once sufficient bioanalytical similarity has been demonstrated, it is acceptable to reduce the extent of nonclinical tests as discussed in Chapter 5. Immunogenicity is one of the major concerns and requires well-developed and characterized assays for detection of an antibody response towards the drug. Chapters 6 and 7 discuss important aspects in the design and validation of these assays, and the possible impact of external factors. Finally, Chapter 8 is devoted in particular to scientific and regulatory issues for the safe approval of biosimilar monoclonal antibodies.

It is clear that the field of biosimilars has evolved considerably and is likely to be subject to significant expansion in the future. Scientific progress in the area of analytical techniques is expected to allow an even more detailed comparative analysis of biosimilars against reference products. One of the key challenges will be to judge in a reliable and predictive manner which differences may, or may not, have an impact on the safety or efficacy of the biosimilar. This may subsequently result in less pre-approval clinical studies for granting market authorization. Finally, the future will have to tell whether, or not, the introduction of biosimilars really contributes towards a sustainable healthcare budget.
ISBN: 978-1-910419-33-5
Publication status: published
KU Leuven publication type: IBe
Appears in Collections:Therapeutic and Diagnostic Antibodies (+)

Files in This Item:

There are no files associated with this item.

 


All items in Lirias are protected by copyright, with all rights reserved.